MalcolmBrennerMD

Pediatric Hematology & Oncology • Houston, TX

Professor of Medicine, Baylor College of Medicine

Join to view full profile

Dr. Brenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Brenner's full profile

Already have an account?

Office
6565 Fannin St

Houston, TX 77030
Phone+1 713-441-1450

Fax+1 713-793-1232
Is this information wrong?

Education & Training

University of Cambridge School of MedicineClass of 1981

Certifications & Licensure

TX State Medical License 2002 - 2025
TN State Medical License 1992 - 2001

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies Start of enrollment: 2000 Aug 01
Terminated
Phase 2
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies Start of enrollment: 2000 Aug 01
Terminated
Phase 2
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis Start of enrollment: 1999 Apr 01
Completed
Phase 2
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Start of enrollment: 2002 Nov 01
Completed
Phase 1, Phase 2
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases Start of enrollment: 2002 Jun 01
Terminated
Phase 1, Phase 2
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation Start of enrollment: 2003 Feb 01
Completed
Phase 1
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells Start of enrollment: 2002 Dec 01
Completed
Phase 1
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine Start of enrollment: 1999 Jun 01
Completed
Phase 1
Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma Start of enrollment: 1997 Nov 01
Completed
Phase 1
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells Start of enrollment: 2003 Jan 01
Completed
Phase 1
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells Start of enrollment: 2005 Sep 01
Withdrawn
Phase 1
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Terminated
Phase 1
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells Start of enrollment: 2006 Dec 01
Completed
Phase 1
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT Start of enrollment: 2002 Mar 01
Terminated
Phase 1
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation Start of enrollment: 2000 Jul 01
Completed
Phase 1
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene Start of enrollment: 2008 Dec 01
Active, not recruiting
Phase 1
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Start of enrollment: 2021 Aug 02
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Meenakshi Hegde, Shoba Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z Gad, Katherine A Janeway, Matthew Campbell, Dolores Mullikin, Ze...> ;Nature Cancer. 2024 Apr 24
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney, Azlann B Arnett, Julien Fleurence, Ramy Sweidan, Thao Wang, Huimin Zhang, Prakash Masan...> ;Research Square. 2024 Apr 3
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from ...
Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Ann M Leen, Mengfen Wu, Li...> ;The Lancet. Oncology. 2024 Apr 1
9 citations
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
Mary K McKenna, Ada Ozcan, Daniel Brenner, Norihiro Watanabe, Maureen Legendre, Dafydd G Thomas, Christopher Ashwood, Richard D Cummings, Challice Bonifant, David M Ma...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
2 citations
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained ...
Kenneth Cornetta, Jing Yao, Kimberley House, Lisa Duffy, Prasad S Adusumilli, Rachel Beyer, Claire Booth, Malcolm Brenner, Kevin Curran, Bambi Grilley, Helen Heslop, C...> ;Molecular Therapy. 2023 Mar 1
13 citations
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.
Spyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, Aster G Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Kimberly Mooney, Natalia Lapteva, Bambi J Gril...> ;Haematologica. 2023 Jul 1
13 citations
Targeting glycans for CAR therapy: The advent of sweet CARs.
Zoe Raglow, Mary Kathryn McKenna, Challice L Bonifant, Wenjing Wang, Marina Pasca di Magliano, Johannes Stadlmann, Josef M Penninger, Richard D Cummings, David M Marko...> ;Molecular Therapy. 2022 Sep 7
4 citations
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
Mary K McKenna, Alexander Englisch, Benjamin Brenner, Tyler Smith, Valentina Hoyos, Masataka Suzuki, Malcolm K Brenner> ;Molecular Therapy. 2021 Dec 1
7 citations
Evidence generation and reproducibility in cell and gene therapy research: A call to action.
Mohamed Abou-El-Enein, Aris Angelis, Frederick R. Appelbaum, Nancy C. Andrews, Susan E. Bates, Arlene S. Bierman, Malcolm K. Brenner, Marina Cavazzana, Michael A. Cali...> ;Molecular Therapy. Methods & Clinical Development. 2021 Sep 10
23 citations
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin Kh Chow, V...> ;The Journal of Clinical Investigation. 2021 Jul 1
16 citations
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
Claudia Manuela Arnone, Vinicia Assunta Polito, Angela Mastronuzzi, Andrea Carai, Francesca Camassei Diomedi, Laura Antonucci, Lucia Lisa Petrilli, Maria Vinci, France...> ;Journal for Immunotherapy of Cancer. 2021 May 1
3 citations
Reversal of exhaustion in engineered T cells.
Maksim Mamonkin, Malcolm K. Brenner> ;Science. 2021 Apr 2
19 citations
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
Amanda Rosewell Shaw, Caroline E. Porter, Tiffany Yip, Way-Champ Mah, Mary K. McKenna, Matthew Dysthe, Youngrock Jung, Robin Parihar, Malcolm K. Brenner, Masataka Suzuki> ;Communications Biology. 2021 Mar 19
24 citations
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
Mary K McKenna, Alexander Englisch, Benjamin Brenner, Tyler Smith, Valentina Hoyos, Masataka Suzuki, Malcolm K Brenner> ;Molecular Therapy. 2021 May 5
12 citations
Taking T-Cell Oncotherapy Off-the-Shelf
Feiyan Mo, Maksim Mamonkin, Malcolm K. Brenner, Helen E. Heslop> ;Trends in Immunology. 2021 Mar 1
22 citations
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
Spyridoula Vasileiou, Premal Lulla, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Wendy L Callejas, Mrinalini Bilgi, Tao Wang, Mengfen J Wu, Rammurti T. Kamble, ...> ;Journal of Clinical Oncology. 2021 Jan 28
62 citations
Engineered off-the-shelf therapeutic T cells resist host immune rejection
Feiyan Mo, Norihiro Watanabe, Mary K. McKenna, M. John Hicks, Madhuwanti Srinivasan, Diogo Gomes-Silva, Erden Atilla, Tyler Smith, Pinar Ataca Atilla, Royce Ma, David ...> ;Nature Biotechnology. 2021 Jan 1
32 citations
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Premal Lulla, Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Suhasini Lulla, George Carrum, Carlos A. Ramos, Rammurti T. Kamble,...> ;Blood. 2021 May 13
9 citations
Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells
Gagan Bajwa, Inès Lanz, Mara Cardenas, Malcolm K. Brenner, Caroline Arber> ;Journal for Immunotherapy of Cancer. 2020 Nov 1
24 citations
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Pinar Ataca Atilla, Mary K. McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Norihiro Watanabe, Brian W. Simons, Alexandra M. Stevens, Michele S. Redell, Hel...> ;Journal for Immunotherapy of Cancer. 2020 Sep 1
21 citations
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.
Premal Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, George Carrum, Carlos A. Ramos, Rammurti T. Kamble, Tao Wang, Meng-Fen Wu, Mrinalini Bilgi, Adrian P. Gee, Shiva...> ;Science Translational Medicine. 2020 Jul 29
183 citations
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Carlos A. Ramos, Natalie S Grover, Anne W. Beaven, Premal Lulla, Meng Fen Wu, Anastasia Ivanova, Tao Wang, Thomas C. Shea, Cliona M. Rooney, Christopher Dittus, Steven...> ;Journal of Clinical Oncology. 2020 Jul 23
88 citations
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Meenakshi Hegde, Sujith K. Joseph, Farzana Pashankar, Christopher DeRenzo, Khaled Sanber, Shoba A. Navai, Tiara T. Byrd, John Hicks, Mina L. Xu, Claudia Gerken, Mamta ...> ;Nature Communications. 2020 Jul 15
19 citations
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells
Jan A. Rath, Gagan Bajwa, B.M. Carreres, Elisabeth Hoyer, Isabelle Gruber, Melisa Martinez-Paniagua, Yi-Ru Yu, Nazila Nouraee, Fatemeh Sadeghi, Meng-Fen Wu, Tao Wang, ...> ;Science Advances. 2020 Jul 1
81 citations
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Caroline E. Porter, Amanda Rosewell Shaw, Youngrock Jung, Tiffany Yip, Patricia Castro, Vlad C. Sandulache, Andrew G. Sikora, Stephen Gottschalk, Michael Ittman, Malco...> ;Molecular Therapy. 2020 May 6
Join now to see all

Journal Articles

EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation
Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
Jordan S Orange, Malcolm K Brenner, Clinical Cancer Research
Onward and Upward for Immuno-Oncology
Malcolm Brenner, MD, Annals of Palliative Medicine

Abstracts/Posters

Single Cell RNA Sequencing Identifies Transcriptional Programs That Enhance Anti-Tumor Function of Transgenic CD4+ T Cells Redirected with TCR and CD8__
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell MalignanciesClinically Relevant Abstract
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
Malcolm K. Brenner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Tessa Therapeutics, Baylor College of Medicine Execute Agreement for Global Commercial Rights to ‘Off-the-Shelf’ CAR-T PlatformNovember 7th, 2022
Cell Therapy Pioneer: Modality Could Be Solution to ‘Pretty Large Cadre’ of DiseasesOctober 17th, 2022
Triumvira Immunologics Establishes Scientific Advisory BoardJanuary 18th, 2022
Join now to see all

Hospital Affiliations

Houston Methodist HospitalHouston, Texas
St. Luke's Health - Baylor St. Luke's Medical CenterHouston, Texas